文献速递肾癌与肾肿瘤

替沃扎尼对比索拉非尼三线或四线治疗转移性肾细胞癌的最终总生存结果:3期研究

Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.
PubMed 文献 · Eur Urol · 2020-09-13

这项开放标签随机3期试验比较替沃扎尼与索拉非尼在已接受两或三线治疗的转移性肾细胞癌患者中的疗效。先前报告已达到主要终点,替沃扎尼较索拉非尼改善无进展生存(5.6个月 vs 3.9个月;HR 0.73,95%CI 0.56-0.94;p=0.016)。本次最终总生存分析显示两组无差异(HR 0.97,95%CI 0.75-1.24)。鉴于其活性及独特耐受性,替沃扎尼是经治转移性肾细胞癌的治疗选择。

要点

  • 替沃扎尼较索拉非尼改善经治mRCC的无进展生存(5.6 vs 3.9个月;HR 0.73)。
  • 最终总生存分析显示替沃扎尼与索拉非尼无差异(HR 0.97,95%CI 0.75-1.24)。
  • 替沃扎尼可作为已接受两或三线治疗的mRCC患者的治疗选择。

核心结论

  • 在已接受两或三线治疗的转移性肾细胞癌患者中,替沃扎尼对比索拉非尼未显示总生存差异(HR 0.97,95%CI 0.75-1.24)。

研究设计与样本

  • 开放标签、随机3期试验,比较替沃扎尼与索拉非尼在已接受两或三线治疗的转移性肾细胞癌患者中的疗效。

主要发现

  • 替沃扎尼较索拉非尼改善无进展生存(5.6个月 vs 3.9个月;HR 0.73,95%CI 0.56-0.94;p=0.016)。
  • 最终总生存分析显示替沃扎尼与索拉非尼无差异(HR 0.97,95%CI 0.75-1.24)。

临床怎么用

  • 对于已接受两或三线治疗的转移性肾细胞癌患者,替沃扎尼可作为一种治疗选择,考虑其活性与独特耐受性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tivozanib is a potent and selective inhibitor of the VEGF receptor. In an open-label, randomized phase 3 trial, we compared tivozanib to sorafenib in patients with metastatic renal cell carcinoma (mRCC) who had received two or three prior therapies. We have previously reported that the study met its primary endpoint, demonstrating an improvement in progression-free survival with tivozanib versus sorafenib (5.6 mo vs 3.9 mo; hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56-0.94; p=0.016). The current report reflects the final assessment of overall survival, showing no difference between treatment with tivozanib and sorafenib (HR 0.97, 95% CI 0.75-1.24). Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC. PATIENT SUMMARY: We show that tivozanib, a targeted therapy, can delay tumor growth relative to an already approved targeted therapy (sorafenib) in patients with kidney cancer who have received two or three prior treatments. No difference in survival was observed.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Pal SK, Escudier BJ, Atkins MB, et al. Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. Eur Urol. 2020. PMID: 32938569. doi:10.1016/j.eururo.2020.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。